Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024

世界の癌治療用キナーゼ阻害剤市場:Brc-Abl阻害剤/EGFR阻害剤/血管新生阻害剤/BRAF・MEK阻害剤/mTOR阻害剤など

◆タイトル:Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024
◆商品コード:VISG409052
◆調査・発行会社:visiongain
◆発行日:2014年6月
◆ページ数:189
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single user licence(1名使用)GBP1,799 ⇒換算¥273,448見積依頼/購入/質問フォーム
Dept Licence(部署内共有可)GBP2,999 ⇒換算¥455,848見積依頼/購入/質問フォーム
Site Licence(同一国内社内共有可)GBP4,999 ⇒換算¥759,848見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"世界の癌治療用キナーゼ阻害剤市場:Brc-Abl阻害剤/EGFR阻害剤/血管新生阻害剤/BRAF・MEK阻害剤/mTOR阻害剤など"について調査・分析し、レポートサマリー、世界市場規模・市場予測、地域別市場分析、主要国別市場分析、市場環境分析、研究開発パイプライン分析、専門家の見解、主要企業分析、結論などの情報をお届けいたします。

Kinase inhibitors – a new study showing you trends, R&D and predicted revenues
Do you want to find sales potentials of kinase inhibitors? Now get the latest analysis for those cancer treatments. There you explore developments, other trends, results, opportunities and revenue forecasts.

Visiongain’s new report shows you what’s possible for drugs using protein kinase inhibition and related technology. There avoid missing out in data. Instead find progress in that industry and market, discovering expected advances and sales. See now how you can gain.

You assess trends, technologies and products, benefiting your reputation for technological, medical and commercial insight.

Progress of that industry – see what’s possible for those anti-cancer medicines
There you explore the future of those therapies. Read on to investigate that industry and see how high its future sales could go.

Forecasts and other information showing technical, clinical and commercial possibilities
That new study gives you sales predictions to 2024 at overall world market, submarket, company, product and national level. See what the future holds. For those drugs you investigate where demand and money lie.

There hear what’s possible. And avoid struggles to find information. Besides giving revenue predictions, that new analysis shows historical results, growth rates and market shares.

In that work you discover 77 tables, 81 charts and an interview with a company. There help your research, analyses and decisions, also benefiting your influence.

And the following sections explain what our new investigation gives you.

Forecasting of that world market and its segments
What’s the potential of that biomedical industry? What’re the secrets of its progress? Find in our report overall world revenue to 2024 from inhibition of protein kinases.

There also find individual revenue predictions to 2024 – with discussions – for seven submarkets at world level:
• Bcr-Abl inhibitors
• Angiogenesis inhibitors
• EGFR inhibitors
• mTOR inhibitors
• Other kinase agents
• BRAF and MEK products
• Generic drugs (generics) and related medicines.

You assess outlooks for expansion in trade, hearing where potential sales increases exist. That work investigates products, uses and revenues past and future. Find what’s possible.

Our study also explores competition. There you see what’s happening for developers, producers and sellers of kinase inhibiting agents, understanding challenges, trends and outlooks. You also explore revenues by product.

Drug forecasts – existing and expected therapies
Discover sales potentials for leading brands, too, seeing how they can compete and succeed. How will 35 cancer treatments perform to 2024 at world level?

Our work shows you individual revenue predictions for 24 top products, including Gleevec, Sprycel, Tasigna, Tarceva and Iressa. It also gives sales predictions for 11 expected drugs, including Palbociclib, Bemaciclib, Alectinib, Ceritinib and Idelalisib.

Also that work splits its overall world market into geographical forecasts.

Healthcare in national markets – what outlooks for that business?
Advances in pharmaceutical biotechnology and healthcare expand use of anti-cancer drugs, including kinase inhibitors. See prospects for developed and developing regions.

Our analyses show you individual revenue forecasts to 2024 for 11 countries:
• United States (US)
• Japan
• Germany, France, UK, Italy and Spain (EU5), also with overall EU prediction
• Brazil, Russia, India and China (BRIC nations).

There you find countries with highest revenues, demand and potential sales. Explore progress, needs and opportunities, seeing how you can gain.

Also how do events, challenges and advances in technology affect that industry and market? Our work shows you, discussing progress, policies and trends.

Forces affecting developers, producers and sellers of those pharmaceuticals
The report explains issues, events and research and development (R&D) affecting that industry and market from 2014, including these:
• Scope of protein kinases in oncology – R&D from 2014
• Cyclin-dependent kinase 4/6 inhibitors in development
• Anaplastic lymphoma kinase (alk) compounds in testing
• Bruton’s tyrosine kinase and PI3K agents for the future
• MEK and BRAF inhibition and other mechanisms of action.

And you explore these trends and influences, among others:
• Drug delivery technology to benefit products’ performance and use
• Stratification of patients for clinical and commercial benefits
• Generic competition for small-molecule treatments
• Biological drugs (biologics) – including monoclonal antibodies (mAbs) – giving differentiated mechanisms of action
• Therapeutic targets identified through cancer genomics – scope for novel technologies
• Combination therapies – potential for improvements in treating patients.

There you assess that industry’s strengths, weaknesses, opportunities and threats, also exploring social, technological, economic and political questions. And you get Porter’s Five Forces analysis. Those methods give you feel for that industry, its progress and potential.

You explore what progress, trends and prospects mean. And you discover what benefits and restricts companies, affecting commercial performance.

Kinase inhibitors for cancer – what 2018 market value?
What happens next? From 2014, kinase inhibitors for cancer patients hold great potential for investments, technological advances and sales. Our new report predicts the world market for those products will reach $27.8bn in 2018, with further expansion to 2024.

In particular our study explores activities and potentials of these companies, including individual revenue forecasting to 2024:
• Novartis
• Pfizer
• Roche
• Bristol-Myers Squibb
• Bayer
• GlaxoSmithKline (GSK)
• AstraZeneca.

From 2014 large pharmaceutical firms and biopharma specialists will win in that market. See how, discovering organisations’ potentials.

【レポートの目次】

1. Report Overview
1.1 Overview of the World Market for Those Medicines
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to Anti-Cancer Kinase Inhibitors
2.1 What are Protein Kinases?
2.2 Protein Kinases in Oncology
2.3 Mechanisms for Kinase Inhibition
2.4 Glossary of Terms

3. Anti-Cancer Kinase Inhibitors: World Market 2014-2024
3.1 The Global Market for Anti-Cancer Kinase Inhibitors in 2013
3.1.1 Leading Anti-Cancer Kinase Inhibitors by Sales, 2013
3.1.2 Leading Companies in the Protein Kinase Inhibitor Market
3.2 World Protein Kinase Inhibitors for Oncology Market: Sales Forecast by Class, 2014-2024
3.2.1 Changing Market Shares by Segment 2014-2024
3.2.2 Leading Anti-Cancer Kinase Inhibitors Manufacturers, 2014-2024
3.3 Bcr-Abl Inhibitors Lead the Protein Kinase Inhibitors for Oncology Market in 2013
3.3.1 Bcr-Abl Kinase Inhibitors: Drivers and Restraints 2014-2024
3.4 Imbruvica and Other Novel Kinase Inhibitors Will Eventually Dominate the Market
3.4.1 Other Kinase Inhibitors: Drivers and Restraints, 2014-2024

4. Leading National and Regional Markets, 2014-2024
4.1 Regional Breakdown of the World Protein Kinase Inhibitors for Drugs Treating Cancer
4.2 World Protein Kinase Inhibitors for Oncology Market: Regional Forecast 2014-2024
4.2.1 How Will Regional Market Shares Change Through to 2024?
4.3 The US Anti-Cancer Kinase Inhibitor Market Forecast, 2014-2024
4.4 The US Market: Drivers and Restraints, 2014-2024
4.5 The EU Union Anti-Cancer Kinase Inhibitors Market Forecast, 2014-2024
4.5.1 EU Market: Drivers and Restraints
4.5.2 German Market Forecast, 2014-2024
4.5.3 French Market Forecast, 2014-2024
4.5.4 Italian Market Forecast, 2014-2024
4.5.5 UK Market Forecast, 2014-2024
4.5.6 Spanish Market Forecast, 2014-2024
4.6 The Japanese Anti-Cancer Kinase Inhibitor Market Forecast, 2014-2024
4.7 Forecasting Anti-Cancer Kinase Inhibitor Markets in Developing Countries, 2014-2024
4.7.1 Chinese Market Forecast, 2014-2024
4.7.2 Brazilian Market Forecast, 2014-2024
4.7.3 Russian Market Forecast, 2014-2024
4.7.4 Indian Market Forecast, 2014-2024

5. Leading Anti-Cancer Kinase Inhibitors Products, 2014-2024
5.1 Brc-Abl Inhibitors – Managed Care for Chronic Myeloid Leukaemia
5.1.1 Gleevec (imatinib) – Novartis
5.1.1.1 Historic Sales Performance
5.1.1.2 Lifecycle Management, Generic Challenges and Tasigna
5.1.1.3 Gleevec Forecast, 2014-2024
5.1.2 Sprycel (dasatanib) – Bristol-Myers Squibb
5.1.2.1 Patents and Market Exclusivity
5.1.2.2 Historic Sales Performance
5.1.2.3 Sprycel Forecast, 2014-2024
5.1.3 Tasigna (nilotinib) – Novartis
5.1.3.1 Indications and Market Exclusivity
5.1.3.2 Historic Sales Performance
5.1.3.3 Tasigna Forecast, 2014-2024
5.1.4 Bosulif (bosutinib) – Pfizer
5.1.4.1 Bosulif Forecast, 2014-2024
5.1.5 Iclusig (ponatinib) – ARIAD Pharmaceuticals
5.1.5.1 Iclusig Forecast, 2014-2024
5.2 EGFR Inhibitors
5.2.1 Tarceva (erlotinib) – Roche/Astellas
5.2.1.1 Patent Litigation and Market Exclusivity
5.2.1.2 Historic Sales Performance, 2004-2012
5.2.1.3 Tarceva Forecast, 2014-2024
5.2.2 Iressa (gefitinib) – AstraZeneca
5.2.2.1 Historic Sales Performance, 2003-2012
5.2.2.2 Iressa Forecast, 2014-2024
5.2.3 Gilotrif (afatinib) – Boehringer Ingelheim
5.2.3.1 Gilotrif Forecast, 2014-2024
5.3 Angiogenesis Inhibitors
5.3.1 Nexavar (sorafenib) – Bayer/Onyx
5.3.1.1 Historic Sales Performance, 2006-2012
5.3.1.2 Nexavar Forecast, 2014-2024
5.3.2 Sutent (sunitinib) – Pfizer
5.3.2.1 Historic Sales Performance, 2006-2012
5.3.2.2 Sutent Forecast, 2014-2024
5.3.3 Votrient (pazopanib) – GSK
5.3.3.1 Historic Sales Performance, 2010-2012
5.3.3.2 Votrient Forecast, 2014-2024
5.3.4 Inlyta (axitinib) – Pfizer
5.3.4.1 Inlyta Forecast, 2014-2024
5.4 BRAF and MEK Inhibitors
5.4.1 Zelboraf (vemurafenib) – Roche/Daiichi Sankyo
5.4.1.1 Zelboraf Forecast, 2014-2024
5.4.2 Mekinist (trametinib) and Tafinlar (dabrafenib) – GSK
5.4.2.1 Mekinist Forecast, 2014-2024
5.4.2.2 Tafinlar Forecast, 2014-2024
5.5 mTOR Inhibitors
5.5.1 Afinitor (everolimus) – Novartis
5.5.1.1 Patents and Market Exclusivity
5.5.1.2 Historic Sales Performance
5.5.1.3 Afinitor Forecast, 2014-2024
5.5.2 Torisel (temsirolimus) – Pfizer
5.5.2.1 Torisel Forecast, 2014-2024
5.6 Other leading Anticancer Kinase Inhibitors
5.6.1 Imbruvica (ibrutinib) –J&J/Pharmacyclics
5.6.1.1 Imbruvica Forecast, 2014-2024
5.6.2 Jakafi (ruxolitinib) – Novartis/Incyte
5.6.2.1 Jakafi Forecast, 2014-2024
5.6.3 Xalkori (crizotinib) – Pfizer
5.6.3.1 Xalkori Forecast, 2014-2024
5.6.4 Cometriq (cabozantinib) – Exelixis
5.6.4.1 Cometriq Forecast, 2014-2024
5.6.5 Caprelsa (vandetanib) – AstraZeneca
5.6.5.1 Caprelsa Forecast, 2014-2024
5.6.6 Tykerb (lapatinib) – GSK
5.6.6.1 Historic Sales Performance, 2007-2012
5.6.6.2 Tykerb Forecast, 2014-2024
5.6.7 Stivarga (regorafenib) – Bayer
5.6.7.1 Stivarga Forecast, 2014-2024

6. Anti-Cancer Kinase Inhibitors: R&D Pipeline, 2014-2024
6.1 Cyclin-Dependent Kinase 4/6 Inhibitors in Development
6.1.1 Palbociclib – Pfizer
6.1.1.1 Palbociclib Forecast, 2014-2024
6.1.2 LEE-011 – Novartis
6.1.2.1 LEE-011 Forecast, 2014-2024
6.1.3 Bemaciclib (LY2835219) – Eli Lilly
6.1.3.1 Bemaciclib Forecast, 2014-2024
6.2 Anaplastic Lymphoma Kinase (ALK) Inhibitors In Development
6.2.1 Alectinib – Roche
6.2.1.1 Alectinib Forecast, 2014-2024
6.2.2 Ceritinib (LDK378) – Novartis
6.2.2.1 Ceritinib Forecast, 2014-2024
6.2.3 AP26113 – ARIAD
6.3 Bruton’s Tyrosine Kinase and PI3K Inhibitors in Development
6.3.1 Idelalisib – Gilead
6.3.1.1 Idelalisib Forecast, 2014-2024
6.3.2 RG7601 (ABT-199) – Roche/AbbVie
6.3.2.1 ABT-199 Sales Forecast, 2014-2024
6.3.3 IPI-145 – Infinity Pharmaceuticals
6.3.3.1 IPI-145 Forecast, 2014-2024
6.3.4 Buparlisib (BKM120) – Novartis
6.3.4.1 Buparlisib Forecast, 2014-2024
6.3.5 ONO-4059 – Ono Pharmaceuticals
6.3.6 Copanlisib (BAY 80-6946) – Bayer
6.3.7 Pictilisib (GDC-0941) – Roche
6.3.8 BEZ235 – Novartis
6.4 MEK and BRAF Inhibitors in Development
6.4.1 Cobimetinib (GDC-0973) – Roche
6.4.1.1 Cobimetinib Forecast, 2014-2024
6.4.2 Encorafenib (LGX818) – Novartis
6.4.3 Binimetinib (MEK162) – Novartis
6.4.4 Selumetinib (AZD 6244) – AstraZeneca
6.5 Other Kinase Inhibitors in Development
6.5.1 Volasertib – Boehringer Ingelheim
6.5.1.1 Volasertib Forecast, 2014-2024
6.5.2 Neratinib (PB272) – Puma Biotechnology
6.5.3 Tivantinib (ARQ197) – Daiichi Sankyo
6.5.4 Dovotinib (TKI258) – Novartis
6.5.5 Dacomitinib – Pfizer
6.5.6 CO-1686 – Clovis Oncology

7. Qualitative Analysis of the Anti-Cancer Kinase Inhibitor Market, 2014-2024
7.1 SWOT Analysis of the Protein Kinase Inhibitors for Oncology Market
7.2 Strengths
7.2.1 Oral Dosage Preferred Over Injection
7.2.2 Stratifying Patients Offers Clinical and Commercial Benefits
7.2.3 Targeted Kinase Inhibitor are Generally Well Tolerated
7.2.4 A Strong Pipeline of Novel Inhibitors Will Drive Market Growth
7.3 Weaknesses
7.3.1 Small Molecule Kinase Inhibitors Will Experience Generic Competition
7.3.2 Competitor Biologics Offer Differentiated Mechanisms of Action
7.3.3 Monoclonal Antibodies are More Specific than Small Molecules
7.4 Opportunities
7.4.1 Novel Targets Identified Through Cancer Genomics
7.4.2 Combination Therapies Bring Additive Benefits
7.4.3 Commercial Success Leveraged by Clinical Benefit
7.5 Threats
7.5.1 Small Molecules Generics Are Easy to Produce
7.5.2 Individual Kinase Targets are Rapidly Becoming Crowded
7.6 STEP Analysis of the Protein Kinase Inhibitors for Oncology Market
7.7 Porter’s Five Forces Analysis of the Anti-Cancer Kinase Inhibitor Market, 2014-2024
7.7.1 Rivalry Among Competitors
7.7.2 Threat of New Entrants
7.7.3 Power of Suppliers
7.7.4 Power of Buyers
7.7.5 Threat of Substitutes

8. Research Interview
8.1 Interview with Dr Lawrence Bloch, Chief Finance and Business Officer, Infinity Pharmaceuticals, United States
8.1.1 Positioning a Novel Therapeutic in Blood Cancer Indications
8.1.2 Combining Therapies Offers Significant Benefit to Patients
8.1.3 Potential in Rheumatoid Arthritis and Blood Cancers

9. Conclusions
9.1 The Global Anti-Cancer Kinase Inhibitors Market to 2024
9.1.1 A Robust Pipeline of Innovative Drugs Driving Market Growth
9.2 Leading National Markets for Anti-Cancer Kinase Inhibitors to 2024

List of Tables
Table 1.1 Forecast Regional and National Anti-Cancer Kinase Inhibitor Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%) 2013-2018
Table 1.2 Forecast Regional and National Anti-Cancer Kinase Inhibitor Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%) 2018-2024
Table 1.3 Foreign Currency Exchange Rates Utilised: 2013 Average Exchange Rate to $US
Table 3.1 Global Market for Anti-Cancer Kinase Inhibitors: Market Size ($bn), Market Share (%), 2013
Table 3.2 Top Five Anti-Cancer Kinase Inhibitors by Revenue: Company, Molecular Target, Indication(s), Global Revenue , 2013
Table 3.3 Leading Companies in the Anti-Cancer Kinase Inhibitor Market: Revenue ($bn), Market Share (%), 2013
Table 3.4 Forecast Global Market for Anti-Cancer Kinase Inhibitors by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2014-2018
Table 3.5 Forecast Global Market for Anti-Cancer Kinase Inhibitors by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2018-2024
Table 3.6 Forecast Global Market for Anti-Cancer Kinase Inhibitors by Class: Market Shares (%), 2013-2024
Table 3.7 Forecast Leading Anti-Cancer Kinase Inhibitors Manufacturers: Product Revenues ($bn), 2014-2018
Table 3.8 Forecast Leading Anti-Cancer Kinase Inhibitors Manufacturers: Product Revenues ($bn), 2018-2024
Table 3.9 Forecast Global Market for Bcr-Abl Kinase Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2013-2024
Table 3.10 Forecast Global Market for Other Kinase Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2013-2024
Table 4.1 Regional and National Breakdown of the Anti-Cancer Kinase Inhibitor Market: Market Sizes ($bn), Market Shares (%), 2013
Table 4.2 Forecast Regional and National Anti-Cancer Kinase Inhibitor Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%) 2013-2018
Table 4.3 Forecast Regional and National Anti-Cancer Kinase Inhibitor Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%) 2018-2024
Table 4.4 Forecast Regional and National Anti-Cancer Kinase Inhibitor Markets: Market Shares (%), 2013-2024
Table 4.5 Forecast US Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 4.6 Forecast EU Anti-Cancer Kinase Inhibitor Market: Market Sizes ($bn), Annual Growth (%), EU Market Shares (%), CAGRs (%), 2013-2018
Table 4.7 Forecast EU Anti-Cancer Kinase Inhibitor Market: Market Sizes ($bn), Annual Growth (%), EU Market Shares (%), CAGRs (%), 2018-2024
Table 4.8 Forecast German Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 4.9 Forecast French Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 4.10 Forecast Italian Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 4.11 Forecast UK Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 4.12 Forecast Spanish Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 4.13 Forecast Japanese Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 4.14 Forecast Anti-Cancer Kinase Inhibitor Markets in the BRIC Nations: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2013-2018
Table 4.15 Forecast Anti-Cancer Kinase Inhibitor Markets in the BRIC Nations: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2018-2024
Table 4.16 Forecast Chinese Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 4.17 Forecast Brazilian Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 4.18 Forecast Russian Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 4.19 Forecast Indian Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 5.1 Historic Gleevec Revenue ($bn), Growth (%), 9 year CAGR (%), 2003-2012
Table 5.2 Gleevec Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 5.3 Historic Sprycel Revenue ($bn), Growth (%), 6 year CAGR (%), 2006-2012
Table 5.4 Sprycel Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 5.5 Historic Tasigna Revenue ($bn), Growth (%), 4 year CAGR (%), 2008-2012
Table 5.6 Tasigna Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 5.7 Bosulif Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 5.8 Iclusig Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 5.9 Historic Tarceva Revenue ($bn), Annual Growth (%), CAGR (%), 2004-2012
Table 5.10 Tarceva Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 5.11 Historic Iressa Revenue ($bn), Annual Growth (%), CAGR (%), 2003-2012
Table 5.12 Iressa Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 5.13 Gilotrif Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 5.14 Historic Nexavar Revenue ($bn), Annual Growth (%), 6 Year CAGR (%), 2006-2012
Table 5.15 Nexavar Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 5.16 Historic Sutent Revenue ($bn), Annual Growth (%), 6 Year CAGR (%), 2006-2012
Table 5.17 Sutent Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 5.18 Historic Votrient Revenue ($bn), Annual Growth (%), 2 Year CAGR (%), 2010-2012
Table 5.19 Votrient Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 5.20 Inlyta Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 5.21 Zelboraf Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 5.22 Mekinist Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 5.23 Tafinlar Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 5.24 Historic Afinitor Revenue ($bn), Annual Growth (%), 3 Year CAGR (%), 2009-2012
Table 5.25 Afinitor Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 5.26 Torisel Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 5.27 Imbruvica Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 5.28 Jakafi Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 5.29 Xalkori Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 5.30 Cometriq Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 5.31 Caprelsa Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 5.32 Historic Tykerb Revenue: Revenue ($bn), Annual Growth (%), CAGR (%), 2007-2012
Table 5.33 Tykerb Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 5.34 Stivarga Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 6.1 Palbociclib Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR from Launch Year (%), 2015-2024
Table 6.2 LEE-011 Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR from Launch Year (%), 2017-2024
Table 6.3 Bemaciclib Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR from Launch Year (%), 2017-2024
Table 6.4 Alectinib Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR from Launch Year (%), 2015-2024
Table 6.5 Ceritinib Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR from Launch Year (%), 2014-2024
Table 6.6 Idelalisib Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR from Launch Year (%), 2014-2024
Table 6.7 ABT-199 Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR from Launch Year (%), 2016-2024
Table 6.8 IPI-145 Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR from Launch Year (%), 2016-2024
Table 6.9 Buparlisib Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR from Launch Year (%), 2017-2024
Table 6.10 Cobimetinib Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR from Launch Year (%), 2015-2024
Table 6.11 Volasertib Revenue Forecast: Revenue ($bn), Annual Growth (%), CAGR from Launch Year (%), 2017-2024
Table 7.1 Social, Technological, Economic, and Political Factors (STEP) Affecting the Anti-Cancer Kinase Inhibitor Market, 2014
Table 9.1 Anti-Cancer Kinase Inhibitor Market Forecasts by Class: Market Size ($bn), Market Share (%), 11 Year CAGR (%), 2013, 2018, and 2024
Table 9.2 Anti-Cancer Kinase Inhibitor Market Forecasts by Region: Market Size ($bn), Market Share (%), 11 Year CAGR (%), 2013, 2018, and 2024

List of Figures
Figure 1.1 Forecast Global Population Over the Age of 65 Years Old (millions), Annual Growth Rate (%), 2013-2024
Figure 1.2 Anti-Cancer Kinase Inhibitor Market Segmentation, 2014
Figure 3.1 Global Market for Anti-Cancer Kinase Inhibitors: Market Shares by Class (%), 2013
Figure 3.2 Top Five Anti-Cancer Kinase Inhibitors by Revenue: Market Shares, 2013
Figure 3.3 Leading Companies in the Protein Kinase Inhibitor Market: Market Shares (%), 2013
Figure 3.4 Forecast Global Market for Anti-Cancer Kinase Inhibitors by Class: Market Sizes ($bn), 2013-2024
Figure 3.5 Forecast Global Market for Anti-Cancer Kinase Inhibitors by Class: Market Shares (%), 2018
Figure 3.6 Forecast Global Market for Anti-Cancer Kinase Inhibitors by Class: Market Shares (%), 2024
Figure 3.7 Forecast Leading Anti-Cancer Kinase Inhibitors Manufacturers: Product Revenues ($bn), 2013-2024
Figure 3.8 Forecast Global Market for Bcr-Abl Kinase Inhibitors: Revenue ($bn), 2013-2024
Figure 3.9 Bcr-Abl Kinase Inhibitor Market: Drivers and Restraints, 2014-2024
Figure 3.10 Forecast Global Market for Other Kinase Inhibitors: Revenue ($bn), 2013-2024
Figure 3.11 Other Kinase Inhibitor Markets: Drivers and Restraints, 2014-2024
Figure 4.1 Regional and National Breakdown of the Anti-Cancer Kinase Inhibitor Market: Market Shares (%), 2013
Figure 4.2 Forecast Regional and National Anti-Cancer Kinase Inhibitor Markets: Market Sizes ($bn), 2013-2024
Figure 4.3 Forecast Regional and National Anti-Cancer Kinase Inhibitor Markets: Market Shares (%), 2018
Figure 4.4 Forecast Regional and National Anti-Cancer Kinase Inhibitor Markets: Market Shares (%), 2024
Figure 4.5 Forecast US Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), 2013-2024
Figure 4.6 US Anti-Cancer Kinase Inhibitor Market: Drivers and Restraints, 2014-2024
Figure 4.7 EU Market for Anti-Cancer Kinase Inhibitors by Nation: Market Shares (%), 2013
Figure 4.8 Forecast EU Anti-Cancer Kinase Inhibitor Market: Market Sizes ($bn), 2013-2024
Figure 4.9 EU Kinase Inhibitor Market: Drivers and Restraints, 2014-2024
Figure 4.10 Forecast German Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), 2013-2024
Figure 4.11 Forecast French Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), 2013-2024
Figure 4.12 Forecast Italian Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), 2013-2024
Figure 4.13 Forecast Anti-Cancer Kinase Inhibitor Market in the UK: Market Size ($bn), 2013-2024
Figure 4.14 Forecast Spanish Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), 2013-2024
Figure 4.15 Forecast Japanese Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
Figure 4.16 Forecast Anti-Cancer Kinase Inhibitor Markets in the BRIC Nations: Market Size ($bn), 2013-2024
Figure 4.17 Forecast Chinese Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), 2013-2024
Figure 4.18 Forecast Brazilian Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), 2013-2024
Figure 4.19 Forecast Russian Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), 2013-2024
Figure 4.20 Forecast Indian Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), 2013-2024
Figure 5.1 Historic Gleevec Revenue ($bn), 2003-2012
Figure 5.2 Gleevec Revenue Forecast: Revenue ($bn), 2013-2024
Figure 5.3 Historic Sprycel Revenue ($bn), 2006-2012
Figure 5.4 Sprycel Revenue Forecast: Revenue ($bn), 2013-2024
Figure 5.5 Historic Tasigna Revenue ($bn), 2008-2012
Figure 5.6 Tasigna Revenue Forecast: Revenue ($bn), 2013-2024
Figure 5.7 Bosulif Revenue Forecast: Revenue ($bn), 2013-2024
Figure 5.8 Iclusig Revenue Forecast: Revenue ($bn), 2013-2024
Figure 5.9 Historic Tarceva Revenue ($bn), 2004-2012
Figure 5.10 Tarceva Revenue Forecast: Revenue ($bn), 2013-2024
Figure 5.11 Historic Iressa Revenue ($bn), 2003-2012
Figure 5.12 Iressa Revenue Forecast: Revenue ($bn), 2013-2024
Figure 5.13 Gilotrif Revenue Forecast: Revenue ($bn), 2013-2024
Figure 5.14 Historic Nexavar Revenue ($bn), 2006-2012
Figure 5.15 Nexavar Revenue Forecast: Revenue ($bn), 2013-2024
Figure 5.16 Historic Sutent Revenue ($bn), 2006-2012
Figure 5.17 Sutent Revenue Forecast: Revenue ($bn), 2013-2024
Figure 5.18 Historic Votrient Revenue ($bn), 2010-2012
Figure 5.19 Votrient Revenue Forecast: Revenue ($bn), 2013-2024
Figure 5.20 Inlyta Revenue Forecast: Revenue ($bn), 2013-2024
Figure 5.21 Zelboraf Revenue Forecast: Revenue ($bn), 2013-2024
Figure 5.22 Mekinist Revenue Forecast: Revenue ($bn), 2013-2024
Figure 5.23 Tafinlar Revenue Forecast: Revenue ($bn), 2013-2024
Figure 5.24 Historic Afinitor Revenue ($bn), 2009-2012
Figure 5.25 Afinitor Revenue Forecast: Revenue ($bn), 2013-2024
Figure 5.26 Torisel Revenue Forecast: Revenue ($bn), 2013-2024
Figure 5.27 Imbruvica Revenue Forecast: Revenue ($bn), 2013-2024
Figure 5.28 Jakafi Revenue Forecast: Revenue ($bn), 2013-2024
Figure 5.29 Xalkori Revenue Forecast: Revenue ($bn), 2013-2024
Figure 5.30 Cometriq Revenue Forecast: Revenue ($bn), 2013-2024
Figure 5.31 Caprelsa Revenue Forecast: Revenue ($bn), 2013-2024
Figure 5.32 Historic Tykerb Revenue ($bn), 2007-2012
Figure 5.33 Tykerb Revenue Forecast: Revenue ($bn), 2013-2024
Figure 5.34 Stivarga Revenue Forecast: Revenue ($bn), 2013-2024
Figure 6.1 Palbociclib Revenue Forecast: Revenue ($bn), 2015-2024
Figure 6.2 LEE-011 Revenue Forecast: Revenue ($bn), 2017-2024
Figure 6.3 Bemaciclib Revenue Forecast: Revenue ($bn), 2017-2024
Figure 6.4 Alectinib Revenue Forecast: Revenue ($bn), 2015-2024
Figure 6.5 Ceritinib Revenue Forecast: Revenue ($bn), 2014-2024
Figure 6.6 Idelalisib Revenue Forecast: Revenue ($bn), 2014-2024
Figure 6.7 ABT-199 Revenue Forecast: Revenue ($bn), 2016-2024
Figure 6.8 IPI-145 Revenue Forecast: Revenue ($bn), 2016-2024
Figure 6.9 Buparlisib Revenue Forecast: Revenue ($bn), 2017-2024
Figure 6.10 Cobimetinib Revenue Forecast: Revenue ($bn), 2015-2024
Figure 6.11 Volasertib Revenue Forecast: Revenue ($bn), 2017-2024
Figure 7.1 Porter’s Five Forces Analysis of the Protein Kinase Inhibitors for Oncology Market, 2014-2024
Figure 9.1 Anti-Cancer Kinase Inhibitor Market Forecasts by Class: Market Sizes ($bn), 2013, 2018, and 2024
Figure 9.2 Anti-Cancer Kinase Inhibitor Market Forecasts by Region: Market Size ($bn), 2013, 2018, and 2024

★調査レポート[世界の癌治療用キナーゼ阻害剤市場:Brc-Abl阻害剤/EGFR阻害剤/血管新生阻害剤/BRAF・MEK阻害剤/mTOR阻害剤など] ( Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 / VISG409052) 販売に関する免責事項
[世界の癌治療用キナーゼ阻害剤市場:Brc-Abl阻害剤/EGFR阻害剤/血管新生阻害剤/BRAF・MEK阻害剤/mTOR阻害剤など] ( Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 / VISG409052) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆